A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression



Status:Recruiting
Conditions:Alzheimer Disease, Neurology, Neurology, Psychiatric, Psychiatric
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:50 - Any
Updated:2/13/2019
Start Date:May 4, 2017
End Date:January 2021
Contact:Study Director
Email:choruspharma@lists.lilly.com

Use our guide to learn which trials are right for you!

Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression

A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and
Aggression


Inclusion Criteria:

- Females must be of non-childbearing potential, defined as women greater than or equal
to (≥) 60 years of age, postmenopausal women ≥50 and less than(<) 60 years of age who
have had a cessation of menses for at least 12 months, or women who are congenitally
or surgically sterile

- Males must agree to use 2 forms of highly effective birth control with female partners
of childbearing potential while enrolled in the study, and for at least 28 days
following the last dose

- Ambulatory (with or without walking device) with a stable gait

- Have an Mini-Mental State Examination (MMSE) score of 10 to 24

- Meet clinical criteria for one of the following disorders: dementia associated with
Parkinson's disease, dementia with Lewy bodies, possible or probable Alzheimer's
disease, frontotemporal degeneration spectrum disorders, vascular dementia

- Able to communicate verbally

- Have an NPI score of ≥4 on either individual item (delusions or hallucinations) or ≥6
on the Psychosis Subscale (combined delusions and hallucinations), or an NPI score of
≥4 on agitation/aggression domain

- Have a reliable caregiver who provides written informed consent to participate and who
is in frequent contact with the patient (defined as spending at least 4 hours/day at
least 4 days/week with the patient and who is knowledgeable about the patient's
daytime and nighttime behaviors). The caregiver must be able to communicate with site
personnel, and opinion of the investigator, must understand the written
protocol-specified questionnaires. If a caregiver cannot continue, one replacement
caregiver will be allowed if the above criterion is met

- Must be on a stable dose of cholinesterase inhibitor and/or memantine, if applicable

- If taking antipsychotic drugs or any drug intended to treat psychosis, must be on a
stable treatment regimen for ≥1 month prior to the study

- Have venous access sufficient to allow for blood sampling per the protocol

- Have clinical laboratory test results within normal reference range for the population
or investigative site

- Are capable of participating in all study assessments

- Are able and willing to provide consent (patients and caregivers)

Exclusion Criteria:

- Have a history of significant psychotic disorders (including, schizophrenia,
delusional disorder, substance abuse psychosis that lasted over 6 months, major
depressive disorder or bipolar disorder with psychotic episodes)

- Has a history of ischemic stroke within the last 12 months or any evidence of
hemorrhagic stroke

- Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) <45
milliliters per minute per 1.73 square meters (ml/min/1.73m2)

- Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or
oncologic comorbidities that could impact patient safety and study participation over
10 weeks

- Have a history of seizures or other condition that would place the patient at
increased risk of seizures.

- Are, in the investigator's judgment, at risk for suicide, or as indicated by the
Columbia Suicide Severity Rating Scale (C-SSRS)

- Have a Fridericia's corrected QT interval (QTcF) greater than (>) 450 milliseconds
(ms) for males or 470 ms for females

- Are currently enrolled in any other clinical trial involving an investigational
product or any other type of medical research judged not to be scientifically or
medically compatible with this study

- Have participated, within the last 30 days, in a clinical trial involving an
investigational product. If the previous investigational product has a long half-life,
at least 3 months (or more) must have passed

- In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
study
We found this trial at
17
sites
Miami Springs, Florida 33166
Principal Investigator: Jose Gamez
Phone: 305-820-3381
?
mi
from
Miami Springs, FL
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Jean Fils
Phone: 813-974-9958
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Boca Raton, Florida 33486
Principal Investigator: Jonathan Harris
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Brooksville, Florida
Principal Investigator: James Andersen
Phone: 352-597-8839
?
mi
from
Brooksville, FL
Click here to add this to my saved trials
Dayton, Ohio 45414
Principal Investigator: Joel Vandersluis
Phone: 937-224-8200
?
mi
from
Dayton, OH
Click here to add this to my saved trials
East Syracuse, New York 13057
Principal Investigator: Karl Hafner
Phone: 315-529-0766
?
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Fairfield, Connecticut 06824
Principal Investigator: Srinath Kadimi
Phone: 203-333-1151
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
Hialeah, Florida 33016
Principal Investigator: Jose Gamez
Phone: 305-805-0921
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Manchester, New Jersey 08759
Principal Investigator: Joshua Shua Haim
Phone: 732-657-6100
?
mi
from
Manchester, NJ
Click here to add this to my saved trials
Newmarket, Ontario
Principal Investigator: Sam Henein, MD
Phone: 905-898-7582
?
mi
from
Newmarket,
Click here to add this to my saved trials
CNS
Orlando, Florida 32801
Principal Investigator: Linda Harper
Phone: 407-425-5100
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Overland Park, Kansas 66212
Principal Investigator: Jeffrey Kaplan
Phone: 913-438-0868
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Pasadena, California 91105
Principal Investigator: Richard Shubin
Phone: 626-566-2866
?
mi
from
Pasadena, CA
Click here to add this to my saved trials
Port Charlotte, Florida 33980
Principal Investigator: Ramon Gil, MD
Phone: 941-743-4987
?
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Saint Petersburg, Florida 33709
Principal Investigator: Gigi Lefebvre
Phone: 727-347-8839
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
851 Olive Street
Shreveport, Louisiana 71104
Principal Investigator: J G Booker, MD
Phone: 318-227-9600
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Staten Island, New York 10312
Principal Investigator: Mark DiBuono
Phone: 718-317-5522
?
mi
from
Staten Island, NY
Click here to add this to my saved trials